| Literature DB >> 26594626 |
A Gulberti1, C K E Moll1, W Hamel2, C Buhmann3, J A Koeppen2, K Boelmans4, S Zittel5, C Gerloff3, M Westphal2, T R Schneider1, A K Engel1.
Abstract
Cortex-basal ganglia circuits participate in motor timing and temporal perception, and are important for the dynamic configuration of sensorimotor networks in response to exogenous demands. In Parkinson's disease (PD) patients, rhythmic auditory stimulation (RAS) induces motor performance benefits. Hitherto, little is known concerning contributions of the basal ganglia to sensory facilitation and cortical responses to RAS in PD. Therefore, we conducted an EEG study in 12 PD patients before and after surgery for subthalamic nucleus deep brain stimulation (STN-DBS) and in 12 age-matched controls. Here we investigated the effects of levodopa and STN-DBS on resting-state EEG and on the cortical-response profile to slow and fast RAS in a passive-listening paradigm focusing on beta-band oscillations, which are important for auditory-motor coupling. The beta-modulation profile to RAS in healthy participants was characterized by local peaks preceding and following auditory stimuli. In PD patients RAS failed to induce pre-stimulus beta increases. The absence of pre-stimulus beta-band modulation may contribute to impaired rhythm perception in PD. Moreover, post-stimulus beta-band responses were highly abnormal during fast RAS in PD patients. Treatment with levodopa and STN-DBS reinstated a post-stimulus beta-modulation profile similar to controls, while STN-DBS reduced beta-band power in the resting-state. The treatment-sensitivity of beta oscillations suggests that STN-DBS may specifically improve timekeeping functions of cortical beta oscillations during fast auditory pacing.Entities:
Keywords: Beta oscillations; Deep brain stimulation; Interval timing; Parkinson's disease; Subthalamic nucleus
Mesh:
Substances:
Year: 2015 PMID: 26594626 PMCID: PMC4596926 DOI: 10.1016/j.nicl.2015.09.013
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Clinical and demographic characteristics.
| Case | Gender | Disease | H&Y | Pre-op | Pre-op UPDRS | DBS parameters for: | Post-op | Post-op UPDRS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dopa-OFF | Dopa-ON | Dopa-OFF | Dopa-OFF | Dopa-ON | |||||||
| 1 | m, 66 | 11 | 3.5 | 2022 mg | 28 | 14 | 130 Hz, 1−, 4.0 V, 60 µs | 1357 mg | 28 | 13 | N/A |
| 2 | m, 60 | 12 | 2 | 1049 mg | 26 | 9 | 240 Hz, 1+, 2−, 3−, 4.9 V, 120 µs | 962 mg | N/A | N/A | N/A |
| 3 | f, 57 | 12 | 2.5 | 1422 mg | 20 | 9 | 130 Hz, 1−, 2−, 2.2 V, 60 µs | 582 mg | N/A | 2 | 1 |
| 4 | f, 54 | 20 | 3 | 1241 mg | 22 | 11 | 130 Hz, 1−, 2−, 3.0 V, 60 µs | 597 mg | 26 | 23 | 17 |
| 5 | f, 66 | 14 | 3 | 760 mg | 48 | 27 | 130 Hz, 1−, 2−, 3.9 V, 60 µs | 938 mg | 44 | 25 | 19 |
| 6 | f, 69 | 12 | 3 | 806 mg | 47 | 42 | 200 Hz, 1−, 2−, 3.2 V, 60 µs | 660 mg | 38 | 24 | 16 |
| 7 | m, 68 | 6 | 2 | 972 mg | 32 | 18 | 210 Hz, 1−, 2−, 3.2 V, 60 µs | 549 mg | 33 | 12 | 10 |
| 8 | m, 56 | 20 | 3 | 1131 mg | 57 | 17 | 130 Hz, 1−, 3.2 V, 60 µs | 635 mg | 57 | 25 | 10 |
| 9 | f, 68 | 13 | 4 | 1431 mg | 26 | 16 | 130 Hz, 2−, 1.9 V, 60 µs | 497 mg | 44 | 27 | 19 |
| 10 | m, 57 | 15 | 3 | 1437 mg | 23 | 18 | 130 Hz, 1−, 2−, 3.0V, 60 µs | 943 mg | 52 | 32 | 27 |
| 11 | f, 59 | 11 | 3 | 397 mg | 26 | 12 | 200 Hz, 2−, 2.0 V, 60 µs | 56 mg | 41 | 22 | 15 |
| 12 | f, 53 | 11 | 2 | 912 mg | 31 | 17 | 130 Hz, 1−, 2−, 2.3 V, 60 µs | 180 mg | 37 | 18 | 14 |
Column “H&Y”: Hoehn & Yahr stages. Columns “Pre-op medication”, “Post-op medication”: levodopa equivalent daily doses (LEDD). Column “ DBS parameters”: stimulation frequency (Hz), active contacts, impulse amplitude (V), impulse width (µs) for left and right electrode, respectively. For the left electrode (first row), contact 0 was the most ventral and contact 3 was the most dorsal. For the right electrode (second row), contact 4 (or 8 in case of Activa PC stimulator) was the most ventral and contact 7 (or 11 in case of Activa PC stimulator) was the most dorsal.
Fig. 1Effects of treatment on resting-state EEG in the central ROI. Analysis of absolute and relative power in controls and in patients for the four therapy conditions. Absolute and relative power spectra were subdivided into five frequency bands (delta, 2–4 Hz; theta, 4–8 Hz; alpha, 8–13 Hz; beta, 13–30 Hz; gamma, 30–48 Hz). (A) Comparison of absolute power spectra. Inset, location of the seven averaged electrodes of the central ROI used for analysis of power. (B) Topographies of absolute power for controls and patient groups. (C) Absolute power in the five frequency bands. Inset, enlarged version of the distribution for absolute beta-band power. (D) Relative power in the five frequency bands. Error bars indicate SEM.
Repeated measures ANOVA for effects of treatment and group on resting-state EEG.
| Repeated measures ANOVA | Factors | Interaction of factors | p-values of post-hoc analyses for: | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| df | f | p | df | f | p | Delta | Theta | Alpha | Beta | Gamma | |
| Relative power | |||||||||||
| DOPA-OFF vs. DOPA-ON | |||||||||||
| Frequency-Bands | 4,44 | 3.787 | .048 | .044 | |||||||
| Levodopa | |||||||||||
| DOPA-OFF vs. OFF-DBS | |||||||||||
| Frequency-Bands | 4,44 | 6.547 | .005 | 4,44 | 8.779 | .003 | .027 | .017 | |||
| Surgery | 1,11 | .297 | .597 | ||||||||
| DOPA-OFF vs. ON-DBS | |||||||||||
| Frequency-Bands | 4,44 | 3.831 | .039 | ||||||||
| Surgery | 1,11 | .086 | .775 | ||||||||
| DOPA-OFF vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 1.178 | .317 | .015 | |||||||
| Group | 1,22 | 7.139 | .014 | ||||||||
| DOPA-ON vs. OFF-DBS | |||||||||||
| Frequency-Bands | 4,44 | 3.845 | .034 | .018 | |||||||
| Surgery | 1,11 | 3.511 | .088 | ||||||||
| DOPA-ON vs. ON-DBS | |||||||||||
| Frequency-Bands | 4,44 | 5.345 | .013 | 4,44 | 2.625 | .047 | .041 | .015 | |||
| Surgery | 1,11 | 3.543 | .087 | ||||||||
| DOPA-ON vs. controls | |||||||||||
| Frequency-Bands | 4,88 | .180 | .842 | ||||||||
| Group | 1,22 | 4.454 | .046 | ||||||||
| OFF-DBS vs. ON−DBS | |||||||||||
| Frequency-Bands | 4,44 | .979 | .404 | ||||||||
| DBS | 1,11 | .348 | .567 | ||||||||
| OFF-DBS vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 3.335 | .014 | .037 | .049 | ||||||
| Group | 1,22 | 8.709 | .007 | ||||||||
| ON-DBS vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 1.640 | .195 | .034 | |||||||
| Group | 1,22 | 6.414 | .019 | ||||||||
| Absolute power | |||||||||||
| DOPA-OFF vs. DOPA-ON | |||||||||||
| Frequency-Bands | .016 | ||||||||||
| Levodopa | 1,11 | .600 | .455 | ||||||||
| DOPA-OFF vs. OFF-DBS | |||||||||||
| Frequency-Bands | 4,44 | 8.625 | .005 | .013 | .037 | ||||||
| Surgery | 1,11 | .584 | .461 | ||||||||
| DOPA-OFF vs. ON-DBS | |||||||||||
| Frequency-Bands | |||||||||||
| Surgery | 1,11 | 2.391 | .150 | ||||||||
| DOPA-OFF vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 1.122 | .335 | .050 | .030 | ||||||
| Group | |||||||||||
| DOPA-ON vs. OFF-DBS | |||||||||||
| Frequency-Bands | 4,44 | 3.535 | .049 | .038 | |||||||
| Surgery | 1,11 | .045 | .836 | ||||||||
| DOPA-ON vs. ON-DBS | |||||||||||
| Frequency-Bands | 4,44 | 2.492 | .105 | .020 | |||||||
| Surgery | 1,11 | 11.963 | .005 | ||||||||
| DOPA-ON vs. controls | |||||||||||
| Frequency-Bands | 4,88 | .192 | .837 | ||||||||
| Group | |||||||||||
| OFF-DBS vs. ON-DBS | |||||||||||
| Frequency-Bands | 4,44 | 1.108 | .350 | .039 | .025 | ||||||
| DBS | |||||||||||
| OFF-DBS vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 3.035 | .021 | .021 | .018 | ||||||
| Group | |||||||||||
| ON-DBS vs. controls | |||||||||||
| Frequency-Bands | 4,88 | 1.423 | .249 | .026 | .022 | .044 | |||||
| Group | 1,22 | 9.359 | .006 | ||||||||
The reported values are degrees of freedom (df), F- and p-values for all the performed repeated measures ANOVA for both relative and absolute power changes. The within-subjects factors are Frequency-Bands (delta, theta, alpha, beta, gamma) and Treatment (Levodopa, Surgery, DBS). The between-subjects factor is Group (patients vs. controls). Results of the repeated measures ANOVA with p values still significant after Bonferroni corrections for the 20 separate ANOVAs are highlighted in bold (i.e., p < 0.0025), while results with p-values between ≥0.05 and ≤0.06 are reported in underlined font. If significant effects of factor Treatment or significant interactions between factor Treatment and factor Frequency-Bands were found in the ANOVA, post-hoc p-values for t-test comparisons between single frequency bands are reported. For post-hoc tests, p-values still significant after Bonferroni corrections are reported in bold (i.e., p < 0.01).
Fig. 3Mean differences and time courses of beta-band total power. (A−H, top panels) Mean power differences at slow RAS (auditory stimulation at 1, 1.5 and 2 Hz) and fast RAS (auditory stimulation at 4, 4.5 and 5 Hz). Unmasked regions in the plots show significantly different z-score clusters (A−H, bottom panels). Time courses of beta-band power at slow and fast RAS. Arrowheads indicate the pre-stimulus beta power increase (−70–0 ms) observed in controls. Gray shaded areas in the bottom panels show significantly different beta-band changes. The “fast RAS” group contains auditory pacing frequencies up to 5 Hz, i.e., with an inter-stimulus interval (ISI) interval of 200 ms. Note that the epochs plotted here are longer than ISIs for the “fast RAS” condition and thus contain responses to more than one stimulus. The peri-stimulus frames marked in the panels represent the time interval used for statistical testing of differences of event-related power changes for the entire considered frequency range (3–80 Hz; upper panels) and for beta-power time courses (for details see methods section). Testing was confined to this time interval to avoid overlapping with preceding or successive stimulus events. All time–frequency plots and power time courses display signal change (in %) relative to the average across the entire data epoch.
Fig. 2Mean total power and power time courses. (A–E) Effects of slow RAS on total power in controls and in patients for the four therapeutic conditions. Top panels show time–frequency plots of the total power averaged across rhythmic auditory stimulation at 1, 1.5 and 2 Hz. Two peri-stimulus response components were identified in mean total power (A): (I) pre-stimulus power increase involving in particular beta frequencies (13–30 Hz, −70–0 ms); (II) an early power increase (4–80 Hz, 0–120 ms). Bottom panels show peri-stimulus total power time courses for the theta-, alpha-, beta- and gamma-band. (F–J) Effects of fast RAS on total power. Top panels show time–frequency plots of the total power averaged across rhythmic auditory stimulation at 4, 4.5 and 5 Hz. Boxes in (F) indicate the same two response components as in (A). Bottom panels show peri-stimulus total power time courses. The “fast RAS” group contains auditory pacing frequencies up to 5 Hz, i.e., with an inter-stimulus interval (ISI) of 200 ms. Note that the epochs plotted here are longer than ISIs for the “fast RAS” condition and thus contain responses to more than one stimulus. All time–frequency plots and power time courses display signal change (in %) relative to the average across the entire data epoch.
Fig. 4ITC spectral characteristics and time courses. (A–E) Effects of slow RAS on ITC in controls and in patients for the four therapy conditions. Top panels show time–frequency plots of the ITC computed across all trials with auditory stimulation at 1, 1.5 and 2 Hz. The boxes in the upper panels of (A) indicate the position of the two power-response components as described in Fig. 2. Bottom panels show ITC courses for the theta-, alpha-, beta- and gamma-band. Note that only response component II shows phase-locking to the stimulus. (F–J) Effects of fast RAS on ITC. Top panels show time–frequency plots of the ITC computed across all trials with auditory stimulation at 4, 4.5 and 5 Hz. Boxes in (F) indicate the same two response components as in (A). Bottom panels show ITC time courses. The “fast RAS” group contains auditory pacing frequencies up to 5 Hz, i.e., with an inter-stimulus interval (ISI) of 200 ms. Note that the epochs plotted here are longer than ISIs for the “fast RAS” condition and thus contain responses to more than one stimulus. This also explains the higher baseline offset for fast RAS (0.2) than for slow RAS (0.1), since the mean ITC-value across the whole epoch served as baseline.